Overall, these studies showed that adjunctive therapy with IFN-γ by aerosol, intramuscular, or subcutaneous routes could be useful to treat MDR-TB patients, but further controlled clinical trials are needed in order to establish the role of IFN-γ in the treatment of TB [58, 60–63]. This evidence concerns the gene IFNG and tuberculosis.